T2 Biosystems strong buy rating!

https://www.nasdaq.com/de/symbol/srne/real-time  

https://www.nasdaq.com/de/symbol/ttoo/real-time  

https://www.analystratings.com/articles/...buy-on-t2-biosystems-ttoo/  

zu sein. Da könnte bald das Gap geschlossen werden....

https://www.nasdaq.com/de/symbol/ttoo/real-time  

https://www.nasdaq.com/de/symbol/ttoo/real-time  

http://www.globenewswire.com/news-release/2019/05/...al-Meetings.html



https://seekingalpha.com/article/...ions-suggest-100-percent-downside  

https://www.nasdaq.com/de/symbol/ttoo/real-time  

2,50 sollten schon das erste Ziel sein

https://www.nasdaq.com/de/symbol/ttoo/real-time  

 

T2 Biosystems meldet Zahlen für Q2/19

• Umsatz 2 Mio. $
  
• Verlust 16 Mio. $
  
• Cash 28 Mio. $
  
• fragwürdige Finanzierung
  

Financing Agreement Highlights:

• The Company entered into two financing agreements that enables the potential access to up to $60 million of additional capital, potentially strengthening its financial position.
  
• Entered into an At-the-Market (ATM) equity offering agreement with Canaccord Genuity LLC pursuant to which Canaccord will, at the Company’s option, use reasonable best efforts to sell up to $30 million of our common stock at our direction.
  
• Entered into common stock purchase and registration rights agreements with Lincoln Park Capital Fund, LLC  (LPC), a Chicago-based institutional investor, under which we will have the right and the sole discretion to sell to LPC up to $30 million worth of shares over a 36-month period at market rates based on closing prices in the past 10 days from when a sales of shares may occur, subject to certain limitations under the agreement as further described below under the section titled "Financing Agreement Details".
  

http://investors.t2biosystems.com/news-releases/...ancial-results-and

 

https://seekingalpha.com/news/...rcent-premarket-q2-miss-guidance-cut  

https://www.globenewswire.com/news-release/2019/...am-Infections.html  

T2 erhält Funding von BARDA

"...announced today that it has been awarded a milestone-based contract of initial value of $6 million with a potential value of up to $69 million, if all contract options are exercised, from the Biomedical Advanced Research and Development Authority (BARDA) ..."

http://investors.t2biosystems.com/news-releases/...advance-technology

 

 

 

 

You are fucking nuts .... bist im falschen Forum oder on drugs? LOL  

 

Ich weiß ja nicht,’wann “du Doof” eingestiegen bist aber ich bin gut im Gewinn. Was ist bei dir schief gelaufen, dass du so austickst. Schon mal ärztliche Hilfe in Anspruch genommen?  

Zahlen für Q3/19

• Umsatz 1,6 Mio. $
  

"The Company believes that an additional $40 million of capital is required to achieve neutral cash flow."

http://investors.t2biosystems.com/news-releases/...ancial-highlights#

 

https://old.nasdaq.com/de/symbol/ttoo/real-time  

vorläufige Zahlen

• Q4/19 Umsatz ~3 Mio. $
  
• Ende Q4/19 Cash ~ 11 Mio. $
  
• MK 54 Mio. $
  

http://investors.t2biosystems.com/news-releases/...ourth-quarter-2019

 

Zahlen für 2019

• Umsatz 8,3 Mio. $ (davon 3,1 Mio. $ in Q4)
  
• Verlust 59 Mio. $ (davon 14 Mio. $ in Q4)
  
• Cash 11 Mio. $
  
• negatives Eigenkapital
  
• MK 34 Mio. $
  

"Management projects revenue for the full year 2020 to range from $14.0 million to $17.0 million,including product revenue between $8.0 million and $10.0 million and research and grant contribution revenue of $6.0 million to $7.0 million "

Angesichts des hohen Verlustes und des niedrigen Cashbestands bin ich eher skeptisch was die kurzfristigen Zukunftsaussichten anbetrifft. Siehe auch Posting #70

http://investors.t2biosystems.com/news-releases/...and-full-year-2019

 

MK 25 Mio. $  

siehe #73